This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial
Leukemia Open Access 01 December 2020
-
An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics
Blood Cancer Journal Open Access 14 October 2020
-
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients
Leukemia Open Access 06 June 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bergsagel PL, Kuehl WM . Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005; 23: 6333–6338.
Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23: 2210–2221.
Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 2012; 26: 349–355.
Morgan GJ, Walker BA, Davies FE . The genetic architecture of multiple myeloma. Nat Rev Cancer 2012; 12: 335–348.
Chen J, Lee BH, Williams IR, Kutok JL, Mitsiades CS, Duclos N et al. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene 2005; 24: 8259–8267.
Trudel S, Stewart AK, Rom E, Wei E, Li ZH, Kotzer S et al. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 2006; 107: 4039–4046.
Annunziata CM, Hernandez L, Davis RE, Zingone A, Lamy L, Lam LT et al. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood 2011; 117: 2396–2404.
Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J . Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005; 106: 296–303.
Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010; 376: 1989–1999.
Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003; 101: 1520–1529.
Fonseca R, Van Wier SA, Chng WJ, Ketterling R, Lacy MQ, Dispenzieri A et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 2006; 20: 2034–2040.
Zhan F, Colla S, Wu X, Chen B, Stewart JP, Kuehl WM et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood 2007; 109: 4995–5001.
Zhou Y, Zhang Q, Stephens O, Heuck CJ, Tian E, Sawyer JR et al. Prediction of cytogenetic abnormalities with gene expression profiles. Blood 2012; 119: e148–e150.
Acknowledgements
MFK is funded by the Deutsche Forschungsgemeinschaft (KA 3338/1-1). BAW and CPW are funded by Myeloma UK. We also gratefully acknowledge funding from the National Institute of Health Biomedical Research Centre at the Royal Marsden Hospital.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Kaiser, M., Walker, B., Hockley, S. et al. A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR. Leukemia 27, 1754–1757 (2013). https://doi.org/10.1038/leu.2013.12
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2013.12
This article is cited by
-
Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial
Leukemia (2021)
-
An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics
Blood Cancer Journal (2020)
-
Risk Stratification in Multiple Myeloma in Indian Settings
Indian Journal of Hematology and Blood Transfusion (2020)
-
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients
Leukemia (2018)
-
Nucleic acid based risk assessment and staging for clinical practice in multiple myeloma
Annals of Hematology (2018)